Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AZR-MD-001 in MGD and CLD
NCT03972501Phase 2Completed
- Sponsor
- Azura Ophthalmics
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of selenium sulfide ophthalmic ointment in meibomian gland dysfunction (MGD), Contact lens discomfort (CLD), sponsored by Azura Ophthalmics. Started Oct 2019; status: completed.
02
Drugs
selenium sulfide ophthalmic ointment
03
Conditions
meibomian gland dysfunction (MGD)Contact lens discomfort (CLD)
Beyond the preview
Go deeper on NCT03972501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972501.